WO2016112879A1 - CRYSTALLINE MODIFICATION 2 OF (3/R)-3-AMINO-1-[3-(TRIFLUOROMETHYL)-6,8-DIHYDRO-5H-[1,2,4]TRIAZOLO[4,3-α]PYRAZIN-7-YL]-4-(2,4,5-TRIFLUOROPHENYL)BUTAN-1-ONE L-TARTRATE - Google Patents

CRYSTALLINE MODIFICATION 2 OF (3/R)-3-AMINO-1-[3-(TRIFLUOROMETHYL)-6,8-DIHYDRO-5H-[1,2,4]TRIAZOLO[4,3-α]PYRAZIN-7-YL]-4-(2,4,5-TRIFLUOROPHENYL)BUTAN-1-ONE L-TARTRATE Download PDF

Info

Publication number
WO2016112879A1
WO2016112879A1 PCT/CZ2016/000001 CZ2016000001W WO2016112879A1 WO 2016112879 A1 WO2016112879 A1 WO 2016112879A1 CZ 2016000001 W CZ2016000001 W CZ 2016000001W WO 2016112879 A1 WO2016112879 A1 WO 2016112879A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino
tartrate
dihydro
trifluorophenyl
butan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CZ2016/000001
Other languages
French (fr)
Inventor
Jindrich Richter
Kamal JARRACH
Violetta Kiss
Eszter TIEGER
Jaroslav Havlicek
Ondrej Dammer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zentiva KS
Original Assignee
Zentiva KS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva KS filed Critical Zentiva KS
Publication of WO2016112879A1 publication Critical patent/WO2016112879A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Definitions

  • the present invention relates to crystalline Modification 2 of (3R)-3-amino-l-[3- (trifluoromethyl)-6,8-dihydro-5H-[l i 2,4]triazolo[4,3-a]pyrazin-7-yll-4-(2,4,5- trifluorophenyl)butan-l-one L-tartrate of Formula 1,
  • Sitagliptin is a selective dipeptidyl-peptidase-4 (DPP-4) receptor inhibitor, used for the treatment of diabetes mellitus type 2 controlling the glucose (sugar) level of the blood.
  • DPP-4 is an enzyme that controls the incretin hormones. The level of the incretin hormones increases as an effect of saxagliptin and in parallel, pancreas produces more insulin and the amount of glucose produced by the liver decreases. These effects reduce the blood glucose level and help in the control of type-2 diabetes.
  • Sitagliptin is disclosed and a list of pharmaceutically acceptable salts thereof is generally included in patent WO03004498.
  • WO2004087650 discloses the sitagliptin free base in crystalline form.
  • WO2005003135 claims the dihydrogenphosphate salt of sitagliptin and its crystalline monohydrate. Three crystalline, anhydrous polymorphic forms of sitagliptin phosphate and various solvates are described and disclosed in patent WO2005020920. WO2005030127 claims a fourth anhydrous polymorph of sitagliptin phosphate. The amorphous dihydrogenphosphate is described and disclosed in patent WO2006033848. Further crystalline solid phase of sitagliptin dihydrogenphosphate are described and claimed patents US2009/247532 and WO2010131035. WO2012166420 claims the phosphate salt of sitagliptin in a stoichiometric ratio of 2:1.
  • Crystalline salts of sitagliptin and hydrochloric acid ben, D- and ..-tartaric acid, p- toluenesulfonic acid, benzenesulfonic acid and (lS)-(+)- and fl/?H-j-camphorsulfonic acid a[- e disclosed in patent WO2005072530.
  • WO 2009085990 claims crystalline salts of sitagliptin formed with sulfonic acid, hydrobromic acid, methanesulfonic acid, acetic acid, benzoic acid, oxalic acid, succinic acid, lactic acid and fumaric acid.
  • WO 2010000469 claims various polymorphic forms of salts of sitagliptin and hydrochloric acid, fumaric acid, sulfuric acid, succinic acid, glycolic acid, maleic acid, methanesulfonic acid, malic acid, phosphoric acid, lactic acid and citric acid. Salts of sitagliptin formed with ethanesulfonic acid, lactic acid, thiocyanic acid and glutaric acid are disclosed in patent WO2010012781.
  • WO2010092090 discloses sitagliptin salts of (D)- and (ij-glucuronic acid, glutaric acid, sulfuric acid, (D)- and (L)-lactic acids, ethanesulfonic acid, oxalic acid, acetic acid, (D)- and (L)- mandelic acid, capric acid, benzoic acid, hippuric acid, frans-cinnamic acid, malonic acid, citric acid, l-hydroxy-2-naphtolic acid, crotonic acid and ascorbic acid.
  • WO2011018494 claims various crystalline forms of sitagliptin salt formed with fumaric acid.
  • WO2012007455 describes the orotate salt of sitagliptin in amorphous phase.
  • the objective of the present invention to provide a novel crystalline modification of a L-tartrate Salt of sitagliptin with good chemical purity, chemical and physical stability and good processability during its preparation as an active pharmaceutical ingredient. It is very important from economical point of view that the preparation process is suitable for industrial scale application and easily reproducible.
  • the object of the present invention is to provide a novel crystalline modification of (3R)-3- amino-l-[3-(trifluoromethyl)-6,8-dihydro-5H-[l,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5- trifluorophenyl)butan-l-one L-tartrate referred to herein as crystalline Modification 2, in particular in a solid form suitable for oral administration which has advantages over the prior art, for example with respect of stability, solubility of the pharmacologically active compound.
  • the invention further relates to pharmaceutical formulations containing the novel crystalline modification of (BRi-B-amino-l-tB-itrifluoromethy -e ⁇ -dihydro-SH-Il ⁇ iAltriazoloI iS- o]pyrazin-7-yl]-4- ⁇ 2,4,5-trifluorophenyl)butan-l-one L-tartrate referred to herein as crystalline Modification 2.
  • Figure 1 is an XRPD pattern of the crystalline Modification 2 of (3i?)-3-amino-l-[3- (trifluoromethy - ⁇ S-dihydro-SH-t ⁇ triazolo S-olpyrazin-y-yll- -t ⁇ B- trifluorophenyl)butan-l-one L-tartrate
  • Figure 2 is a FTIR spectra of the crystalline Modification 2 of ⁇ 3R)-3-amino-l-[3- (trifluoromethy -e ⁇ S-dihydro-SH-tl ⁇ ltriazolot ⁇ S-olpyrazin-T-yll- -t ⁇ ⁇ - trifluorophenyl)butan-l-one L-tartrate
  • Figure 3 is a Raman spectra of the crystalline Modification 2 of ⁇ 3R)-3-amino-l-[3- (trifluoromethyl)-6,8-dihydro-5H-[l i 2,4]triazolo[4,3-o]pyrazin-7-yl]-4-(2,4,5- trifluorophenyl)butan-l-one L-tartrate
  • Figure 4 is a ⁇ C-ssNMR spectra of the crystalline Modification 2 of ⁇ 3R)-3-amino-l-[3- (trifluoromethyl)-6,8-dihydro-5H-[l,2,4]triazolo[4 J 3- ]pyrazin-7-yl]-4- ⁇ 2 i 4,5- trifluorophenyl)butan-l-one L-tartrate
  • Figure 5 is a 19 F-ssNMR spectra of the crystalline Modification 2 of (3R)-3-amino-l-[3- (trifluoromethyl)-6 J 8-dihydro-5H-[l,2 ; 4]triazolo[4 ; 3-o]pyrazin-7-yl]-4-(2,4,5- trifluorophenyl)butan-l-one L-tartrate
  • Figure 6 is a DCS curve of the crystalline Modification 2 of (3/?)-3-amino-l-[3- (trifluoromethyl)-6,8-dihydro-5H-[l ; 2,4]triazolo[4 / 3-o]pyrazin-7-yl]-4-(2 i 4 / 5- trifluorophenyl)butan-l-one L-tartrate
  • Figure 7 is a TG curve of the crystalline Modification 2 of (3R)-3-amino-l-[3- ⁇ trifluoromethyl)- 6 i 8-dihydro-5H-[l,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-l-one L- tartrate
  • the invention relates to a novel crystalline modification of (3R)-3-amino-l-[3- (trifluoromethyl)-6,8-dihydro-5H-[l,2 J 4]triazolo[4 ; 3-a]pyrazin-7-yl]-4-(2,4,5- trifluorophenyl)butan-l-one L-tartrate referred to herein as crystalline Modification 2, which meets the pharmaceutical requirements regarding the physico-chemical properties and stability and have advantages over the prior art, for example with respect of stability, solubility of the pharmacologically active compound, and which can be produced in reproducible manner even in industrial scale.
  • the novel crystalline Modification 2 of (3 ? ⁇ -3-amino-l-[3-(trifluoromethyl)-6,8-dihydro-5H- [l,2,4]triazolo[4 i 3-a]pyrazin-7-yl]-4- ⁇ 2,4 i 5-trifluorophenyl)butan-l-one L-tartrate according to the invention has the characteristic XRPD pattern as shown in Figure 1. XRPD pattern was recorded on an X-Ray Powder Diffractometer (X'PERT PRO MPD PANalytical).
  • Modification 2 can be further characterized by an FTIR, Raman and solid state NMR spectroscopy investigations.
  • Figure 2 shows the FTIR (Nicolet Thermo 6700) spectrum comprising characteristic peaks at 3446, 3364, 3035, 1668, 1627, 1276, 1148, 1023, 877 and 716 cm "1 and
  • Figure 3 shows the Raman (FT-Raman Bruker RFS 100/S) spectrum comprising characteristic peaks at 3091, 3036, 2970, 2913, 1631, 1512, 1370, 801, 757 and 232 cm "1 .
  • Figure 4 shows the 13 C-ssNMR (Bruker AVANCE 250 MHz) spectrum
  • Figure 5 shows the 19 F-ssNMR (Bruker AVANCE 250 MHz) spectrum.
  • (2,4,5-trifluorophenyl)butan-l-one L-tartrate crystalline Modification 2 can be prepared by a salt formation and crystallization process comprising the steps of
  • step 1) any crystalline solid form of (3/?)-3-amino-l-[3-(trifluoromethyl)-6,8-dihydro-5H- [l,2,4]triazolo[4,3-o]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-l-one L-tartrate can be used as starting material.
  • L-tartrate can be suspended in alcohol- water mixtures, preferably in a methanol-water solvent mixture in a volumetric ratio of 90:10 to 50:50, preferably 60:40.
  • the temperature applied for suspension depends on the initial amount and solid form of the starting material, preferably 20°C -30°C, more preferably 25°C.
  • step 2) the suspension containing (3/?)-3-amino-l-[3-(trifluoromethyl)-6,8-dihydro-5H- [l,2,4]triazolo[4,3-o]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-l-one L-tartrate can be agitated for further 1 to 3 weeks, preferably 2 weeks.
  • step 3) the crystals obtained can be collected by any conventional method, e.g. filtration.
  • the obtained (SRj-B-amino-l-tS-ttrifluoromethy -e ⁇ -dihydro-BH-Il ⁇ triazolo ⁇ S- a]pyrazin-7-yl]-4- ⁇ 2,4,5-trifluorophenyl)butan-l-one L-tartrate crystalline Modification 2 can be dried by vacuum suction or at laboratory condition, preferably by vacuum suction.
  • the slurry was agitated at room temperature for 2 weeks and then the resulted solid was collected by filtration and dried on air by vacuum suction.
  • the slurry was heated up to 50°C with a continuous stirring of 200 rpm.
  • the suspension was stirred for additional 1 hour at 50°C and cooled back to 20°C with a cooling rate of 15°C/h and stirred for 2 hours at that temperature.
  • the product was filtered and dried in vacuum oven at 40°C and 200 mbar for 16 hours.
  • the resulting suspension was stirred for additional 15 minutes at 50°C and cooled to 20°C with a cooling rate of 15°C/h and stirred for 1 hour at that temperature.
  • the product was filtered and dried in vacuum oven at 40°C and 200 mbar for 16 hours.
  • Hi-N R analysis confirmed the structure with a stoichiometry of 1:1.
  • Water content determination resulted in 1.5% of water content.
  • Incident beam optics programmable divergence slits (irradiated length 10 mm), 10 mm mask, 1/ 9 anti-scatter fixed slit, 0.02 rad Soller slits.
  • Diffracted beam optics X'Celerator detector, scanning mode, active length 2.122 Q , 0.02 rad Soller slits, anti-scatter slit 5.0 mm, Ni filter.
  • FTIR spectra were recorded by Nicolet Thermo 6700 spectrometer.
  • ⁇ NMR spectra the Bruker NMR spectrometer AVANCE 500 MHz and DMSO as solvent were used. The stoichiometry of salts were determined from integrals of corresponding signals of API and counterion. C and F ss N R spectra were measured on Bruker 400 WB spectrometer in 4 mm rotors with 13 kHz spinning frequency. The spectra of salts were compared with the spectrum of initial API because the formation of a salt should be accompanied by changes of positions of signals of API and by the presence of signals of counterion.
  • the samples were weighed in aluminium pans and covers (20 ⁇ .) and measured in a nitrogen flow (50 mL/min). Investigations were performed in a temperature range of 25 °C to 300 °C with a heating rate of 10°C/min.
  • the temperatures specified in relation to DSC analyses are the temperatures of the peak maxima and onset temperature of peaks.
  • the specific heat is given in J/g.
  • the weight of the sample was about 3-4 mg.
  • the samples were weighed in aluminium pans (85 ⁇ .) and measured in nitrogen flow. TGA investigations were performed in a temperature range of 25°C to 300°C with a heating rate of 10°C/min.
  • the weight of the sample was about 5-6 mg.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Crystalline Modification 2 of Sitagliptin L-tartrate salt, exhibiting the following characteristic diffraction peaks: 5.83; 15.63; 17.73; 25.58; 26.44 ± 0.2° 2-theta. (Formula)

Description

Crystalline Modification 2 of (3/?)-3-amino-l-[3-(trifluoromethYl)-6,8-dihydro-5H- [1,2,4]ΐπ3ζοΙο[ ,3-σ]ργΓ3Ζϊη-7-νΙΪ-4-(2, ,5-ΙπΑυοΓο Ηθηγ1) υΐ3ΐ -1-οηθ L-tartrate
Technical Field The present invention relates to crystalline Modification 2 of (3R)-3-amino-l-[3- (trifluoromethyl)-6,8-dihydro-5H-[li2,4]triazolo[4,3-a]pyrazin-7-yll-4-(2,4,5- trifluorophenyl)butan-l-one L-tartrate of Formula 1,
Figure imgf000002_0001
process for its preparation, as well as said solid state form for use in pharmaceutical compositions.
Background Art
Sitagliptin is a selective dipeptidyl-peptidase-4 (DPP-4) receptor inhibitor, used for the treatment of diabetes mellitus type 2 controlling the glucose (sugar) level of the blood. DPP-4 is an enzyme that controls the incretin hormones. The level of the incretin hormones increases as an effect of saxagliptin and in parallel, pancreas produces more insulin and the amount of glucose produced by the liver decreases. These effects reduce the blood glucose level and help in the control of type-2 diabetes.
Sitagliptin is disclosed and a list of pharmaceutically acceptable salts thereof is generally included in patent WO03004498.
WO2004087650 discloses the sitagliptin free base in crystalline form.
WO2005003135 claims the dihydrogenphosphate salt of sitagliptin and its crystalline monohydrate. Three crystalline, anhydrous polymorphic forms of sitagliptin phosphate and various solvates are described and disclosed in patent WO2005020920. WO2005030127 claims a fourth anhydrous polymorph of sitagliptin phosphate. The amorphous dihydrogenphosphate is described and disclosed in patent WO2006033848. Further crystalline solid phase of sitagliptin dihydrogenphosphate are described and claimed patents US2009/247532 and WO2010131035. WO2012166420 claims the phosphate salt of sitagliptin in a stoichiometric ratio of 2:1.
Crystalline salts of sitagliptin and hydrochloric acid, ben, D- and ..-tartaric acid, p- toluenesulfonic acid, benzenesulfonic acid and (lS)-(+)- and fl/?H-j-camphorsulfonic acid a[-e disclosed in patent WO2005072530.
WO 2009085990 claims crystalline salts of sitagliptin formed with sulfonic acid, hydrobromic acid, methanesulfonic acid, acetic acid, benzoic acid, oxalic acid, succinic acid, lactic acid and fumaric acid.
WO 2010000469 claims various polymorphic forms of salts of sitagliptin and hydrochloric acid, fumaric acid, sulfuric acid, succinic acid, glycolic acid, maleic acid, methanesulfonic acid, malic acid, phosphoric acid, lactic acid and citric acid. Salts of sitagliptin formed with ethanesulfonic acid, lactic acid, thiocyanic acid and glutaric acid are disclosed in patent WO2010012781.
WO2010092090 discloses sitagliptin salts of (D)- and (ij-glucuronic acid, glutaric acid, sulfuric acid, (D)- and (L)-lactic acids, ethanesulfonic acid, oxalic acid, acetic acid, (D)- and (L)- mandelic acid, capric acid, benzoic acid, hippuric acid, frans-cinnamic acid, malonic acid, citric acid, l-hydroxy-2-naphtolic acid, crotonic acid and ascorbic acid.
WO2011018494 claims various crystalline forms of sitagliptin salt formed with fumaric acid. WO2012007455 describes the orotate salt of sitagliptin in amorphous phase.
Journal of Medicinal Chemistry, 2005, 48, pages 141-151 describes that sitagliptin salt of fumaric acid with a stoichiometric ratio of 2:1 was used for in-vivo studies.
Therefore the objective of the present invention to provide a novel crystalline modification of a L-tartrate Salt of sitagliptin with good chemical purity, chemical and physical stability and good processability during its preparation as an active pharmaceutical ingredient. It is very important from economical point of view that the preparation process is suitable for industrial scale application and easily reproducible.
Summary of the invention The object of the present invention is to provide a novel crystalline modification of (3R)-3- amino-l-[3-(trifluoromethyl)-6,8-dihydro-5H-[l,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5- trifluorophenyl)butan-l-one L-tartrate referred to herein as crystalline Modification 2, in particular in a solid form suitable for oral administration which has advantages over the prior art, for example with respect of stability, solubility of the pharmacologically active compound. The invention further relates to pharmaceutical formulations containing the novel crystalline modification of (BRi-B-amino-l-tB-itrifluoromethy -e^-dihydro-SH-Il^iAltriazoloI iS- o]pyrazin-7-yl]-4-{2,4,5-trifluorophenyl)butan-l-one L-tartrate referred to herein as crystalline Modification 2.
Brief description of the figures
Figure 1 is an XRPD pattern of the crystalline Modification 2 of (3i?)-3-amino-l-[3- (trifluoromethy -^S-dihydro-SH-t^^^triazolo S-olpyrazin-y-yll- -t^^B- trifluorophenyl)butan-l-one L-tartrate
Figure 2 is a FTIR spectra of the crystalline Modification 2 of {3R)-3-amino-l-[3- (trifluoromethy -e^S-dihydro-SH-tl^^ltriazolot^S-olpyrazin-T-yll- -t^ ^- trifluorophenyl)butan-l-one L-tartrate
Figure 3 is a Raman spectra of the crystalline Modification 2 of {3R)-3-amino-l-[3- (trifluoromethyl)-6,8-dihydro-5H-[li2,4]triazolo[4,3-o]pyrazin-7-yl]-4-(2,4,5- trifluorophenyl)butan-l-one L-tartrate
Figure 4 is a ^C-ssNMR spectra of the crystalline Modification 2 of {3R)-3-amino-l-[3- (trifluoromethyl)-6,8-dihydro-5H-[l,2,4]triazolo[4J3- ]pyrazin-7-yl]-4-{2i4,5- trifluorophenyl)butan-l-one L-tartrate
Figure 5 is a 19F-ssNMR spectra of the crystalline Modification 2 of (3R)-3-amino-l-[3- (trifluoromethyl)-6J8-dihydro-5H-[l,2;4]triazolo[4;3-o]pyrazin-7-yl]-4-(2,4,5- trifluorophenyl)butan-l-one L-tartrate
Figure 6 is a DCS curve of the crystalline Modification 2 of (3/?)-3-amino-l-[3- (trifluoromethyl)-6,8-dihydro-5H-[l;2,4]triazolo[4/3-o]pyrazin-7-yl]-4-(2i4/5- trifluorophenyl)butan-l-one L-tartrate
Figure 7 is a TG curve of the crystalline Modification 2 of (3R)-3-amino-l-[3-{trifluoromethyl)- 6i8-dihydro-5H-[l,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-l-one L- tartrate
Detailed description of the invention The invention relates to a novel crystalline modification of (3R)-3-amino-l-[3- (trifluoromethyl)-6,8-dihydro-5H-[l,2J4]triazolo[4;3-a]pyrazin-7-yl]-4-(2,4,5- trifluorophenyl)butan-l-one L-tartrate referred to herein as crystalline Modification 2, which meets the pharmaceutical requirements regarding the physico-chemical properties and stability and have advantages over the prior art, for example with respect of stability, solubility of the pharmacologically active compound, and which can be produced in reproducible manner even in industrial scale. The above aim has been achieved by the novel crystalline modification of {3R)-3-amino-l-[3- (trifluoromethy -^S-dihydro-SH-tl^^ltnazolo^S-alpyrazin-T-yll-^t^^S- trifluorophenyl)butan-l-one L-tartrate referred to herein as crystalline Modification 2.
The novel crystalline modification of (3/?)-3-amino-l-[3-(trifluoromethyl)-6,8-dihydro-5f - [l,2;4]triazolo[4,3-o]pyrazin-7-yl]-4-(2i4J5-trifluorophenyl)butan-l-one L-tartrate referred to herein as crystalline Modification 2 can be obtained with good yield and high purity.
The novel crystalline Modification 2 of (3 ?}-3-amino-l-[3-(trifluoromethyl)-6,8-dihydro-5H- [l,2,4]triazolo[4i3-a]pyrazin-7-yl]-4-{2,4i5-trifluorophenyl)butan-l-one L-tartrate according to the invention has the characteristic XRPD pattern as shown in Figure 1. XRPD pattern was recorded on an X-Ray Powder Diffractometer (X'PERT PRO MPD PANalytical). (3R)-3-Amino- l-tS-itrifluoromethy -^S-dihydro-BH-tl^^ltrtazolo S-aJpyrazin-y-yn^-i^^S- trifluorophenyl)butan-l-one L-tartrate crystalline Modification 2 shows the following powder diffraction peaks as illustrated in Table 1, below:
Figure imgf000005_0001
Table 1 (3R)-3- Amino- l-[3-(trifluoromet^
(2,4,5-trifluorophenyl)butan-l-one L-tartrate crystalline Modification 2 can be further characterized by an FTIR, Raman and solid state NMR spectroscopy investigations. Figure 2 shows the FTIR (Nicolet Thermo 6700) spectrum comprising characteristic peaks at 3446, 3364, 3035, 1668, 1627, 1276, 1148, 1023, 877 and 716 cm"1 and Figure 3 shows the Raman (FT-Raman Bruker RFS 100/S) spectrum comprising characteristic peaks at 3091, 3036, 2970, 2913, 1631, 1512, 1370, 801, 757 and 232 cm"1. Figure 4 shows the 13C-ssNMR (Bruker AVANCE 250 MHz) spectrum and Figure 5 shows the 19F-ssNMR (Bruker AVANCE 250 MHz) spectrum.
(3 ?)-3-Amino-l-[3-(trifluoromethyl)-6,8-dihydro-5H-[l,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-
(2,4,5-trifluorophenyl)butan-l-one L-tartrate crystalline Modification 2 can be further described by thermal analytical methods. Figure 6 shows the DSC (Mettler Toledo DSC 822e) curve measured in the range of 25°C to 300°C and gives a melting process with Tpeak =81.09eC and TPeak,2=197.94°C. Figure 7 shows the TGA (Netzsch TG 209) curve showing a 1.27% weight loss in the range of 25°C-to 300°C.
A process for the preparation of (3R)-3-amino-l-[3-(trifluoromethyl)-6,8-dihydro-5H- [l,2,4]triazolo[4,3-o]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-l-one L-tartrate crystalline Modification 2,
(3R)-3-Amino-l-[3-(trifluoromethyl)-6,8-dihydro-5H-[l,2,4]triazolo[4,3-o]pyrazin-7-yl]-4-
(2,4,5-trifluorophenyl)butan-l-one L-tartrate crystalline Modification 2 can be prepared by a salt formation and crystallization process comprising the steps of
1) suspension of (3R)-3-amino-l-[3-(trifluoromethyl)-6,8-dihydro-5H-[l,2,4]triazolo[4,3- a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-l-one L-tartrate;
2) agitation of suspension;
3) collection of the crystals obtained by filtration and drying.
In step 1) any crystalline solid form of (3/?)-3-amino-l-[3-(trifluoromethyl)-6,8-dihydro-5H- [l,2,4]triazolo[4,3-o]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-l-one L-tartrate can be used as starting material. (3R)-3-Amino-l-[3-(trifluoromethyl)-6,8-dihydro-5H-[l,2,4]triazolo[4,3- o]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-l-one L-tartrate can be suspended in alcohol- water mixtures, preferably in a methanol-water solvent mixture in a volumetric ratio of 90:10 to 50:50, preferably 60:40. The temperature applied for suspension depends on the initial amount and solid form of the starting material, preferably 20°C -30°C, more preferably 25°C.
In step 2) the suspension containing (3/?)-3-amino-l-[3-(trifluoromethyl)-6,8-dihydro-5H- [l,2,4]triazolo[4,3-o]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-l-one L-tartrate can be agitated for further 1 to 3 weeks, preferably 2 weeks. In step 3) the crystals obtained can be collected by any conventional method, e.g. filtration. The obtained (SRj-B-amino-l-tS-ttrifluoromethy -e^-dihydro-BH-Il^^triazolo^S- a]pyrazin-7-yl]-4-{2,4,5-trifluorophenyl)butan-l-one L-tartrate crystalline Modification 2 can be dried by vacuum suction or at laboratory condition, preferably by vacuum suction.
Examples Example 1
Preparation of (3 ?)-3-amino-l-[3-(trifluoromethyl)-6,8-dihydro-5H-[l,2,4]tria2olo[4,3- olpyrazin^-yll-A-^AS-trifluorophenylJbutan-l-one L-tartrate crystalline Modification 2
500 mg (1.228 mmol) of {SRH-amino-l-lB-itrifluoromethylJ-e^-dihydro-SH- [l,2,4]triazolo[4/3-a]pyrazin-7-yl]-4-(2/4,5-trifluorophenyl)butan-l-one L-tartrate was suspended in 7.5 ml of a solvent mixture of methanol and water with a volumetric ratio of 60-40 at room temperature.
The slurry was agitated at room temperature for 2 weeks and then the resulted solid was collected by filtration and dried on air by vacuum suction.
Yield: 76%
HPLC: 99.9%
1H-NM analysis confirmed the structure with a stoichiometry of 1:1.
Water content determination resulted in 1.7% of water content.
Example 2
Preparation of (SRj-S-amino-l-tS-ltrifluoromethylJ-G^-dihydro-SH-tl^^ltriazolo S- a]pyrazin-7-Yl]-4-{2,4,5-trifluorophenYl)butan-l-one L-tartrate crystalline Modification 2
4.04 g (7.250 mmol) of (3/?)-3-amino-l-[3-(trifluoromethyl)-6,8-dihydro-5H- [l,2;4]triazolo[4i3-o]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-l-one L-tartrate was suspended in 81.4 ml of a solvent mixture of water and 2-propanol with a volumetric ratio of 1-10 at room temperature.
The slurry was heated up to 50°C with a continuous stirring of 200 rpm. The suspension was stirred for additional 1 hour at 50°C and cooled back to 20°C with a cooling rate of 15°C/h and stirred for 2 hours at that temperature.
The product was filtered and dried in vacuum oven at 40°C and 200 mbar for 16 hours.
Yield: 96% HPLC: 99.8%
H - R analysis confirmed the structure with a stoichiometry of 1:1.
Water content determination resulted in 1.6% of water content. Example 3
Preparation of (3 ?)-3-amino-l-[3-{trifluoromethyl)-6,8-dihydro-5H-[l,2,4]triazolo[4,3- a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-l-one L-tartrate crystalline Modification 2
1.12 g (2.750 mmol) of (3R)-3-amino-l-[3-(trifluoromethyl)-6,8-dihydro-5H- [lJ2,4]triazolo[4J3-o]pyrazin-7-yl]-4-(2,4i5-trifluorophenyl)butan-l-one was dissolved in 25 mL 2-propanol by heating to 50°C.
0.55 g (3.670 mmol) of L-tartaric acid was dissolved in 2.4 mL of water at room temperature and the solution of L-tartaric acid was added to the solution of (3 ?)-3-amino-l-[3- (trifluoromethyl)-6,8-dihydro-5H-[l,2,4]triazolo[4i3-o]pyrazin-7-yl]-4-(2,4,5- trifluorophenyl)butan-l-one of 50eC.
The resulting suspension was stirred for additional 15 minutes at 50°C and cooled to 20°C with a cooling rate of 15°C/h and stirred for 1 hour at that temperature.
The product was filtered and dried in vacuum oven at 40°C and 200 mbar for 16 hours.
Yield: 65%
HPLC: 99.6%
Hi-N R analysis confirmed the structure with a stoichiometry of 1:1.
Water content determination resulted in 1.5% of water content.
Analysis -XRPD (X-Ray Powder Diffracto etry) Diffractograms were obtained with laboratory X'PERT PRO MPD PANalytical diffractometer with CuKa (λ = 1.542A) radiation.
Generator settings:
- excitation voltage 45 kV
anodic current 40 mA.
Scan description:
scan type - gonio
measurement range 2 - 40s 2Θ
- step size 0.01≤ 2Θ
- time per step: 0.5s. Sample was measured as received (not grinded) on Si substrate (zero-background holder).
Incident beam optics: programmable divergence slits (irradiated length 10 mm), 10 mm mask, 1/ 9 anti-scatter fixed slit, 0.02 rad Soller slits.
Diffracted beam optics: X'Celerator detector, scanning mode, active length 2.122Q, 0.02 rad Soller slits, anti-scatter slit 5.0 mm, Ni filter.
Analysis - FTIR (Fourier-Transformed Infra- Red) spectroscopy
FTIR spectra were recorded by Nicolet Thermo 6700 spectrometer.
General settings:
Number of sample scans: 45
Number of background scans: 45
Resolution: 4.000
Sample gain: 4.0
Optical velocity: 0.6329
Aperture: 100.00
Analysis - Raman spectroscopy
FTIR spectra were recorded by FT-Raman Bruker RFS 100/S Spectrometer
General settings:
Excitation source: Nd-YAG laser (1064 nm)
Applied spectral domain: 3600-200 cm"1
Applied laser power: 250 mW
Detector: liquid nitrogen cooled Ge-diode detector (D418-T)
Resolution: 4 cm"1
Number of accumulations: 256
Scattering geometry: 180° (back scattering)
Aperture: 3.5 mm
Analysis - NMR
For Η NMR spectra the Bruker NMR spectrometer AVANCE 500 MHz and DMSO as solvent were used. The stoichiometry of salts were determined from integrals of corresponding signals of API and counterion. C and F ss N R spectra were measured on Bruker 400 WB spectrometer in 4 mm rotors with 13 kHz spinning frequency. The spectra of salts were compared with the spectrum of initial API because the formation of a salt should be accompanied by changes of positions of signals of API and by the presence of signals of counterion.
Analysis - DSC (Differential Scanning Calorimetry)
DSC measurements were performed on a Mettler Toledo DSC822e instrument.
The samples were weighed in aluminium pans and covers (20 μί.) and measured in a nitrogen flow (50 mL/min). Investigations were performed in a temperature range of 25 °C to 300 °C with a heating rate of 10°C/min. The temperatures specified in relation to DSC analyses are the temperatures of the peak maxima and onset temperature of peaks. The specific heat is given in J/g.
The weight of the sample was about 3-4 mg.
Analysis - TGA (ThermoGravimetric Analysis)
TGA were performed on a Netzsch TG 209 instrument.
The samples were weighed in aluminium pans (85 μΐ.) and measured in nitrogen flow. TGA investigations were performed in a temperature range of 25°C to 300°C with a heating rate of 10°C/min.
The weight of the sample was about 5-6 mg.

Claims

Claims:
1. Crystalline Modification 2 of Sitagliptin L-tartrate salt, exhibiting the following characteristic diffraction peaks: 5.83; 15.63; 17.73; 25.58; 26.44 + 0.2° 2-theta.
2. Crystalline Modification 2 according to claim 1, further exhibiting the following characteristic diffraction peaks: 11.71; 18.27; 20.95; 21.24; 23.57 ± 0.2° 2-theta.
PCT/CZ2016/000001 2015-01-13 2016-01-07 CRYSTALLINE MODIFICATION 2 OF (3/R)-3-AMINO-1-[3-(TRIFLUOROMETHYL)-6,8-DIHYDRO-5H-[1,2,4]TRIAZOLO[4,3-α]PYRAZIN-7-YL]-4-(2,4,5-TRIFLUOROPHENYL)BUTAN-1-ONE L-TARTRATE Ceased WO2016112879A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ2015-30580U 2015-01-13
CZ2015-30580U CZ27898U1 (en) 2015-01-13 2015-01-13 Crystalline modification of 2 L-tartrate (3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4,]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorphenyl)butan-1-one

Publications (1)

Publication Number Publication Date
WO2016112879A1 true WO2016112879A1 (en) 2016-07-21

Family

ID=52630123

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CZ2016/000001 Ceased WO2016112879A1 (en) 2015-01-13 2016-01-07 CRYSTALLINE MODIFICATION 2 OF (3/R)-3-AMINO-1-[3-(TRIFLUOROMETHYL)-6,8-DIHYDRO-5H-[1,2,4]TRIAZOLO[4,3-α]PYRAZIN-7-YL]-4-(2,4,5-TRIFLUOROPHENYL)BUTAN-1-ONE L-TARTRATE

Country Status (2)

Country Link
CZ (1) CZ27898U1 (en)
WO (1) WO2016112879A1 (en)

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003004498A1 (en) 2001-07-06 2003-01-16 Merck & Co., Inc. Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004087650A2 (en) 2003-03-27 2004-10-14 Merck & Co. Inc. Process and intermediates for the preparation of beta-amino acid amide dipeptidyl peptidase-iv inhibitors
WO2005003135A1 (en) 2003-06-24 2005-01-13 Merck & Co., Inc. Phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
WO2005020920A2 (en) 2003-09-02 2005-03-10 Merck & Co., Inc. Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
WO2005030127A2 (en) 2003-09-23 2005-04-07 Merck & Co., Inc. Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
WO2005072530A1 (en) 2004-01-16 2005-08-11 Merck & Co., Inc. Novel crystalline salts of a dipeptidyl peptidase-iv inhibitor
WO2006033848A1 (en) 2004-09-15 2006-03-30 Merck & Co., Inc. Amorphous form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
WO2009085990A2 (en) 2007-12-20 2009-07-09 Dr. Reddy's Laboratories Limited Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
US20090247532A1 (en) 2008-03-28 2009-10-01 Mae De Ltd. Crystalline polymorph of sitagliptin phosphate and its preparation
WO2010000469A2 (en) 2008-07-03 2010-01-07 Ratiopharm Gmbh Crystalline salts of sitagliptin
WO2010012781A2 (en) 2008-07-29 2010-02-04 Medichem, S.A. New crystalline salt forms of a 5,6,7,8-tetrahydro-1,2,4- triazolo[4,3-a]pyrazine derivative
WO2010032264A2 (en) * 2008-08-27 2010-03-25 Cadila Healthcare Limited Improved process for preparation of (2r)-4-oxo-4-[3- (trifluoromethyl)-5,6-dihydro [1,2,4]-triazolo[4,3-a]pyrazin- 7(8h)-yl]-l-(2,4,5-trifluorophenyl)butan-2-amine & new impurities in preparation thereof
WO2010092090A2 (en) 2009-02-11 2010-08-19 Lek Pharmaceuticals D.D. Novel salts of sitagliptin
WO2010131035A1 (en) 2009-05-11 2010-11-18 Generics [Uk] Limited Novel crystalline polymorph of sitagliptin dihydrogen phosphate
WO2011018494A1 (en) 2009-08-13 2011-02-17 Sandoz Ag Crystalline compound of 7-[(3r)-3-amino-1-oxo-4-(2, 4, 5-trifluorphenyl)butyl]-5, 6, 7, 8-tetrahydro-3-(tri fluormethyl)-1, 2, 4 -triazolo[4,3-a]pyrazine
WO2012007455A1 (en) 2010-07-13 2012-01-19 Chemo Iberica, S.A. Process for the preparation of organic salts
WO2012166420A1 (en) 2011-05-27 2012-12-06 Merck Sharp & Dohme Corp. Phosphoric acid salts of sitagliptin
WO2015062562A1 (en) * 2013-11-01 2015-05-07 Zentiva, K.S. A stable polymorph of the salt of (2r)-4-oxo-4-[3-(trifiuoromethyl)-5,6- dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8h)-yl]-l-(2,4,54rifluorophenyl)butan-2-amine with l-tartaric acid

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003004498A1 (en) 2001-07-06 2003-01-16 Merck & Co., Inc. Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
WO2004087650A2 (en) 2003-03-27 2004-10-14 Merck & Co. Inc. Process and intermediates for the preparation of beta-amino acid amide dipeptidyl peptidase-iv inhibitors
WO2005003135A1 (en) 2003-06-24 2005-01-13 Merck & Co., Inc. Phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
WO2005020920A2 (en) 2003-09-02 2005-03-10 Merck & Co., Inc. Novel crystalline forms of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
WO2005030127A2 (en) 2003-09-23 2005-04-07 Merck & Co., Inc. Novel crystalline form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
WO2005072530A1 (en) 2004-01-16 2005-08-11 Merck & Co., Inc. Novel crystalline salts of a dipeptidyl peptidase-iv inhibitor
WO2006033848A1 (en) 2004-09-15 2006-03-30 Merck & Co., Inc. Amorphous form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
WO2009085990A2 (en) 2007-12-20 2009-07-09 Dr. Reddy's Laboratories Limited Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof
US20090247532A1 (en) 2008-03-28 2009-10-01 Mae De Ltd. Crystalline polymorph of sitagliptin phosphate and its preparation
WO2010000469A2 (en) 2008-07-03 2010-01-07 Ratiopharm Gmbh Crystalline salts of sitagliptin
WO2010012781A2 (en) 2008-07-29 2010-02-04 Medichem, S.A. New crystalline salt forms of a 5,6,7,8-tetrahydro-1,2,4- triazolo[4,3-a]pyrazine derivative
WO2010032264A2 (en) * 2008-08-27 2010-03-25 Cadila Healthcare Limited Improved process for preparation of (2r)-4-oxo-4-[3- (trifluoromethyl)-5,6-dihydro [1,2,4]-triazolo[4,3-a]pyrazin- 7(8h)-yl]-l-(2,4,5-trifluorophenyl)butan-2-amine & new impurities in preparation thereof
WO2010092090A2 (en) 2009-02-11 2010-08-19 Lek Pharmaceuticals D.D. Novel salts of sitagliptin
WO2010131035A1 (en) 2009-05-11 2010-11-18 Generics [Uk] Limited Novel crystalline polymorph of sitagliptin dihydrogen phosphate
WO2011018494A1 (en) 2009-08-13 2011-02-17 Sandoz Ag Crystalline compound of 7-[(3r)-3-amino-1-oxo-4-(2, 4, 5-trifluorphenyl)butyl]-5, 6, 7, 8-tetrahydro-3-(tri fluormethyl)-1, 2, 4 -triazolo[4,3-a]pyrazine
WO2012007455A1 (en) 2010-07-13 2012-01-19 Chemo Iberica, S.A. Process for the preparation of organic salts
WO2012166420A1 (en) 2011-05-27 2012-12-06 Merck Sharp & Dohme Corp. Phosphoric acid salts of sitagliptin
WO2015062562A1 (en) * 2013-11-01 2015-05-07 Zentiva, K.S. A stable polymorph of the salt of (2r)-4-oxo-4-[3-(trifiuoromethyl)-5,6- dihydro[l,2,4]triazolo[4,3-a]pyrazin-7(8h)-yl]-l-(2,4,54rifluorophenyl)butan-2-amine with l-tartaric acid

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF MEDICINAL CHEMISTRY, vol. 48, 2005, pages 141 - 151

Also Published As

Publication number Publication date
CZ27898U1 (en) 2015-03-02

Similar Documents

Publication Publication Date Title
USRE48825E1 (en) 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms
WO2017125097A1 (en) Crystalline forms of (3r)-3-cyclopentyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4- yl)pyrazol-l-yl]propanenitrile salts and preparation thereof
EP3344607A1 (en) Solid state forms of selexipag
EP3322709B1 (en) Crystalline forms of (3r)-3-cyclopentyl-3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile salts and preparation thereof
US20080027223A1 (en) Polymorphs of eszopiclone malate
EP3256474B1 (en) Ibrutinib sulphate salt
WO2016127963A1 (en) Solid forms of palbociclib salts
WO2015085972A1 (en) NOVEL SALTS OF 3-(2-IMIDAZO[1,2-b]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-[4-[(4-METHYL- 1-PIPERAZINYL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL] BENZAMIDE
EP3321267A1 (en) Crystalline forms of 2-[1-ethylsulfonyl-3-[7h-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile salts and preparation thereof
WO2016172333A1 (en) A solid state form of perampanel
WO2016112879A1 (en) CRYSTALLINE MODIFICATION 2 OF (3/R)-3-AMINO-1-[3-(TRIFLUOROMETHYL)-6,8-DIHYDRO-5H-[1,2,4]TRIAZOLO[4,3-α]PYRAZIN-7-YL]-4-(2,4,5-TRIFLUOROPHENYL)BUTAN-1-ONE L-TARTRATE
EP2771312B1 (en) Agomelatine-urea complex and crystalline forms thereof
WO2015085973A1 (en) Modifications of 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl] benzamide hydrochloride salt
WO2016112880A1 (en) Crystalline modification 3 of (3r)-3-amino-l-[3-(trifluoromethyl)-6,8-dihydro-5h- [l1,2,4]triazolol[4,3-]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one l-tartrate
KR20160078359A (en) A STABLE POLYMORPH OF THE SALT OF (2R)-4-OXO-4-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-α]PYRAZIN-7(8H)-YL]-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE WITH L-TARTARIC ACID
EP3419964B1 (en) Crystalline modifications of methyl (3z)-3-{[(4-{methyl[(4-methylpiperazin-1-yl)acetyl]amino} phenyl)amino](phenyl)methylidene}-2-oxo-2,3-dihydro-1h-indole-6-carboxylate salts and methods of preparation thereof
KR20260048580A (en) Method for preparing 2-[(3R)-2-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-D]pyrimidine-1-yl]piperidine-1-carbonyl]-4-methyl-4[4-(oxetane-3-yl)piperazine-1-yl]-pent-2-ennitrile and its solvate form
WO2011039670A1 (en) Novel forms of (2,8-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-3,4-dihydro-1h-pyrido[4,3-b] indole)
WO2015067223A1 (en) L-tartrate salt of (1s,3s,5s)-2-[(2s)-2-amino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl) acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile and process for preparation thereof
HK1152231B (en) Substituted heterocycle fused gamma-carbolines solid

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16703418

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16703418

Country of ref document: EP

Kind code of ref document: A1